Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients

Authors:
Publisher website
Google Scholar
Abstract
Pharmacogenetics is a key component of precision medicine that uses genetic information to guide drug selection and dosing decisions.1 More than 100 commercially available drugs in the US contain pharmacogenetic information in the US Food and Drug Administration (FDA) label, including therapeutic management recommendations and warnings about the potential effects on drug safety, response, or potential alterations in pharmacokinetic parameters.2,3 The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes evidence-based, drug-centric, peer-reviewed guidelines for how to translate genetic test results into actionable prescribing decisions.4-6 During the last decade, CPIC has published guidelines on more than 35 gene-drug pairs as CPIC level A, indicating that a prescribing action is recommended when genotype information is available and that the preponderance of evidence is high or moderate in favor of changing prescribing.7

This publication has 50 references indexed in Scilit: